Logo

People in the News: Apr 29, 2010

Apr 29, 2010
Premium

Arrowhead Research, the parent company of Calando Pharmaceuticals, said that it has appointed Andrew von Eschenbach to its scientific advisory board.

Von Eschenbach was previously commissioner of the US Food and Drug Administration. Before that, he was director of the National Cancer Institute. He currently serves as senior director for strategic initiatives at the Center for Health Transformation, a think tank founded by Newt Gingrich.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Arrowhead
RNAi
Calando
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.